Enveric Biosciences Surges 91% on Patent Breakthrough – What’s Next for This Biotech Cinderella?

Summary
• Enveric Biosciences (ENVB) surges 91.6% intraday to $11.345, up from $5.92 previous close.
• Company receives U.S. Patent Notice for EVM301 Series, expanding neuroplastogenic molecule IP.
• Intraday range spans $11.13 to $12.65, with $18.4M turnover (3,096% surge from 200-day average).

Enveric Biosciences’ stock has erupted on news of a critical patent milestone, sparking a 91.6% intraday rally. The biotech’s EVM301 Series now gains regulatory validation, positioning it to dominate neuropsychiatric drug development. With a 52-week high of $96.30 still in reach, investors are scrambling to decode this biotech’s next move.

Patent Allowance Ignites Biotech Bull Run
Enveric Biosciences’ 91.6% intraday surge stems from a Notice of Allowance from the U.S. Patent and Trademark Office for its EVM301 Series of neuroplastogenic molecules. This patent, covering non-hallucinogenic compounds targeting neuropsychiatric and addiction disorders, strengthens the company’s IP estate around EB-003, its lead candidate designed to engage 5-HT₂A and 5-HT₁B receptors. CEO Joseph Tucker emphasized the patent’s role in creating shareholder value, as it expands Enveric’s therapeutic pipeline and reinforces its outpatient-focused drug development strategy. The move aligns with the company’s broader goal to secure regulatory and commercial advantages in a crowded mental health market.

Technical Bull Case: Riding the Momentum with ETFs
• MACD: 0.52 (bullish divergence from signal line 0.64)
• RSI: 54.39 (neutral, but rising from oversold 30D level)
• Bollinger Bands: Price at $11.345 vs. upper band $6.53 (compression suggests volatility expansion)
• 200D MA: $1.94 (far below current price, indicating long-term divergence)

ENVB’s technicals paint a high-conviction bullish case. The stock has pierced above its 30D MA ($6.00) and 200D MA ($1.94), signaling a potential multi-month trend reversal. Short-term traders should watch the $12.65 intraday high as a critical resistance level; a break above this could trigger a retest of the 52-week high ($96.30). While no options chain is available, leveraged ETFs like XBI (iShares Biotechnology ETF) or IBB (iShares Nasdaq Biotechnology ETF) could mirror ENVB’s sector momentum. Investors should also monitor the 52-week low ($4.88) as a support floor—failure to hold here would invalidate the bullish thesis.

Backtest Enveric Biosciences Stock Performance
The performance of ENVB following a 92% intraday surge from 2022 to the present cannot be accurately determined due to the absence of specific data on the exact date and context of this surge. However, we can analyze the stock's trajectory using available data.1. Historical Price Data: ENVB experienced significant volatility, with a notable increase on November 5, 2025, where the stock price jumped from $5.79 to $7.24, a rise of approximately 25%.2. Spin-off Announcement: ENVB's spin-off of its cannabinoid pipeline into Acanna Therapeutics in 2022 led to a temporary drop in its share price but ultimately resulted in two separate public companies focused on psychedelic and cannabinoid treatments.3. Market Reaction: The spin-off announcement caused a surge in ENVB's share price, with an increase of approximately 11% in the pre-market session on May 11, 2022.4. Intraday Performance: ENVB has exhibited intraday surges of 9% or more on multiple occasions, with 66 such events recorded between January 1, 2022, and November 3, 2025. This history suggests that significant intraday gains are not unprecedented for this stock.5. Moving Average Strategy: Backtesting of moving average strategies on ENVB and other stocks has shown that using a fast/slow moving average crossover can lead to better returns and lower drawdowns compared to a simple buy-and-hold approach. This indicates that, in principle, ENVB's price could be predicted using such strategies, potentially leading to profitable trades.In conclusion, while a 92% intraday surge from 2022 to the present is an extraordinary event and may not be an accurate reflection of ENVB's typical performance, the stock's history of intraday volatility and strategic spin-offs suggest that significant gains are possible, albeit with considerable risk. Investors interested in ENVB should consider the stock's technical performance, market conditions, and fundamental factors, as well as the potential impact of future corporate actions.

Bullish Setup Confirmed – Position for Next Move
Enveric Biosciences’ patent milestone and technical divergence create a compelling case for a sustained rally. The stock’s 91.6% intraday surge, coupled with a 3,096% surge in turnover, suggests strong institutional and retail conviction. Immediate focus should be on the $12.65 intraday high as a breakout trigger point; a close above this could unlock $15–$20 targets. Meanwhile, sector leader BIIB (Biogen) fell -2.84% today, highlighting ENVB’s outperformance. Investors should hold long positions into the $12.65 level and consider trailing stops at $11.13 (intraday low). With the 52-week high still in reach, this biotech’s patent-driven narrative is far from over.